MCRB
$9.38
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integr...
Recent News
Seres Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. AP) — Seres Therapeutics Inc. MCRB) on Thursday reported a loss of $15.3 million in its fourth quarter.
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8%
Seres to lay off staff, pause top program in latest reboot
The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).